Immutep (ASX: IMM) Hits Key Phase III Milestone: Buy the Dip or Take Profits Before the Critical Data Readout?

Immutep (ASX: IMM) has pulled back roughly 22 per cent from its recent 52-week high near A$0.46, settling around A$0.36 this week. The selloff comes despite no change to the company’s clinical outlook and follows a strong rally that began in early December after Immutep signed a landmark licensing deal with Dr Reddy’s Laboratories.

What makes the timing interesting is that Immutep just confirmed it has enrolled 378 patients in its Phase III TACTI-004 trial, hitting the halfway mark of its roughly 756-patient target. The trial is running across more than 140 sites in 27 countries, and an independent committee is expected to conduct a critical interim analysis in the coming weeks to assess whether the treatment is showing enough efficacy to continue. For investors, the pullback raises a key question: Is this a chance to buy ahead of a potentially transformative data readout, or is it time to lock in gains before the outcome is known?

Efti’s Opportunity in a US$24 Billion Lung Cancer Market

Immutep’s lead drug, eftilagimod alfa (efti), is being developed to treat non-small cell lung cancer (NSCLC), the deadliest cancer globally, with more than two million new cases every year. The global NSCLC treatment market is estimated at roughly US$24 billion.

The current standard of care combines Merck’s KEYTRUDA with chemotherapy. However, this approach works poorly for patients with low or no PD-L1 expression, a protein used to predict immunotherapy response. These harder-to-treat patients represent approximately two-thirds of all NSCLC cases.

This is where efti stands apart. Results from the INSIGHT-003 trial, presented at ESMO 2025, showed that combining efti with KEYTRUDA and chemotherapy produced a 61.7 per cent response rate in patients with low or no PD-L1, well above the 40.8 per cent historical benchmark. Disease control rates ranged between 86 per cent and 100 per cent across all PD-L1 levels, and the U.S. FDA has granted efti Fast Track designation for first-line NSCLC treatment.

We believe efti’s ability to improve outcomes regardless of PD-L1 levels is its strongest differentiator. If the Phase III confirms these earlier results, Efti could become a new standard of care for a very large group of lung cancer patients.

Dr Reddy’s Deal and Cash Runway Remove Near-Term Funding Risk

One of the biggest risks for clinical-stage biotechs is running out of cash before key data arrives. Immutep has effectively taken that concern off the table.

In December 2025, the company signed a licensing deal with Dr Reddy’s Laboratories for emerging markets, delivering an upfront payment of approximately A$30 million received in January 2026, with up to A$528 million in potential milestone payments plus double-digit royalties on future sales. This deal does more than fund operations. It signals a major pharmaceutical company has done its own due diligence on Efti and sees enough commercial potential to commit meaningful capital.

Combined with A$99.1 million in existing cash at 31 December 2025, Immutep’s pro-forma position now sits at approximately A$129 million, extending its runway well into mid-2027. For investors, this means no imminent dilution risk and enough funding to reach the interim data readout and beyond.

The Investor’s Takeaway – Buy, Wait, or Take Profits?

The bull case has strengthened since the pullback. Analyst consensus targets sit around A$1.30, implying more than 260 per cent upside from the current A$0.36. If the interim analysis delivers a positive result in the coming weeks, the stock could re-rate significantly as the market begins pricing in a genuine shot at regulatory approval.

The bear case is equally clear: this is a binary event. If the independent data monitoring committee determines the trial is unlikely to succeed, the stock would take a sharp hit. Phase III failures in oncology are not uncommon, and earlier-stage data do not guarantee a positive outcome.

We believe the risk-reward is compelling for investors willing to accept binary risk. However, position sizing matters. Given the all-or-nothing nature of the interim data, spreading exposure rather than going all-in seems prudent. Conservative investors may prefer to wait for the readout before taking a position, even if that means paying a higher price for greater certainty.